226 related articles for article (PubMed ID: 32476587)
1. Successful alectinib desensitization in a patient with anaplastic lymphoma kinase-positive adenocarcinoma of the lung and alectinib-induced drug rash.
Anderson BE; Luczak TS; Ries LM; Hoefs GE; Silva-Benedict AC
J Oncol Pharm Pract; 2020 Dec; 26(8):2028-2030. PubMed ID: 32476587
[TBL] [Abstract][Full Text] [Related]
2. Successful oral desensitization against skin rash induced by alectinib in a patient with anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report.
Shirasawa M; Kubotaa M; Harada S; Niwa H; Kusuhara S; Kasajima M; Hiyoshi Y; Ishihara M; Igawa S; Masuda N
Lung Cancer; 2016 Sep; 99():66-8. PubMed ID: 27565916
[TBL] [Abstract][Full Text] [Related]
3. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
4. Severe acute interstitial lung disease in a patient with anaplastic lymphoma kinase rearrangement-positive non-small cell lung cancer treated with alectinib.
Yamamoto Y; Okamoto I; Otsubo K; Iwama E; Hamada N; Harada T; Takayama K; Nakanishi Y
Invest New Drugs; 2015 Oct; 33(5):1148-50. PubMed ID: 26334220
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort.
Bedas A; Peled N; Maimon Rabinovich N; Mishaeli M; Shochat T; Zer A; Rotem O; Allen AM; Bar J; Dudnik E;
Oncol Res Treat; 2019; 42(5):275-282. PubMed ID: 30955009
[TBL] [Abstract][Full Text] [Related]
6. Alectinib for advanced
Ly AC; Olin JL; Smith MB
Am J Health Syst Pharm; 2018 Apr; 75(8):515-522. PubMed ID: 29467147
[TBL] [Abstract][Full Text] [Related]
7. Interstitial lung disease secondary to alectinib after interstitial injury induced by crizotinib.
Kaira K; Naruse I; Shimizu K; Asao T
J Cancer Res Ther; 2020; 16(4):919-921. PubMed ID: 32930141
[TBL] [Abstract][Full Text] [Related]
8. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; PĂ©rol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
9. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial.
Hida T; Nokihara H; Kondo M; Kim YH; Azuma K; Seto T; Takiguchi Y; Nishio M; Yoshioka H; Imamura F; Hotta K; Watanabe S; Goto K; Satouchi M; Kozuki T; Shukuya T; Nakagawa K; Mitsudomi T; Yamamoto N; Asakawa T; Asabe R; Tanaka T; Tamura T
Lancet; 2017 Jul; 390(10089):29-39. PubMed ID: 28501140
[TBL] [Abstract][Full Text] [Related]
10. Alectinib induced CNS radiation necrosis in an ALK+NSCLC patient with a remote (7 years) history of brain radiation.
Ou SH; Weitz M; Jalas JR; Kelly DF; Wong V; Azada MC; Quines O; Klempner SJ
Lung Cancer; 2016 Jun; 96():15-8. PubMed ID: 27133743
[TBL] [Abstract][Full Text] [Related]
11. Interstitial lung disease induced by alectinib (CH5424802/RO5424802).
Ikeda S; Yoshioka H; Arita M; Sakai T; Sone N; Nishiyama A; Niwa T; Hotta M; Tanaka T; Ishida T
Jpn J Clin Oncol; 2015 Feb; 45(2):221-4. PubMed ID: 25398579
[TBL] [Abstract][Full Text] [Related]
12. Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.
Fukano R; Mori T; Sekimizu M; Choi I; Kada A; Saito AM; Asada R; Takeuchi K; Terauchi T; Tateishi U; Horibe K; Nagai H
Cancer Sci; 2020 Dec; 111(12):4540-4547. PubMed ID: 33010107
[TBL] [Abstract][Full Text] [Related]
13. Cost Effectiveness of Ceritinib and Alectinib Versus Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-small-cell Lung Cancer.
Li H; Lai L; Wu B
Clin Drug Investig; 2020 Feb; 40(2):183-189. PubMed ID: 31820329
[TBL] [Abstract][Full Text] [Related]
14. Revisiting a lower starting dose of alectinib in ALK-Positive non-small cell lung cancer.
Sacdalan DB; Lucero JA
Cancer Treat Res Commun; 2021; 27():100319. PubMed ID: 33515938
[TBL] [Abstract][Full Text] [Related]
15. Successful Drug Rechallenge Following Severe Acute Alectinib-induced Interstitial Lung Disease in a Patient With Advanced ALK-rearranged Lung Adenocarcinoma.
Gadotti LL; Nogueira Amorim Canedo FS; Ribeiro MFSA; Sacardo KP; Saddi R; Machado Alessi JV; de Abreu Testagrossa L; Katz A
Clin Lung Cancer; 2021 May; 22(3):e481-e486. PubMed ID: 32771343
[No Abstract] [Full Text] [Related]
16. Alectinib (Alecensa)-induced reversible grade IV nephrotoxicity: a case report and review of the literature.
Ramachandran P; Morcus R; Tahir M; Onukogu I; Spinowitz B; Wang JC
J Med Case Rep; 2018 Oct; 12(1):303. PubMed ID: 30336782
[TBL] [Abstract][Full Text] [Related]
17. Exposure-Response Analyses of Anaplastic Lymphoma Kinase Inhibitors Crizotinib and Alectinib in Non-Small Cell Lung Cancer Patients.
Groenland SL; Geel DR; Janssen JM; de Vries N; Rosing H; Beijnen JH; Burgers JA; Smit EF; Huitema ADR; Steeghs N
Clin Pharmacol Ther; 2021 Feb; 109(2):394-402. PubMed ID: 32686074
[TBL] [Abstract][Full Text] [Related]
18. Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study.
Zhou C; Kim SW; Reungwetwattana T; Zhou J; Zhang Y; He J; Yang JJ; Cheng Y; Lee SH; Bu L; Xu T; Yang L; Wang C; Liu T; Morcos PN; Lu Y; Zhang L
Lancet Respir Med; 2019 May; 7(5):437-446. PubMed ID: 30981696
[TBL] [Abstract][Full Text] [Related]
19. Successful rechallenge of alectinib after remission of severe alectinib-induced interstitial lung disease.
Huang JR; Chou CW; Chao HS
J Oncol Pharm Pract; 2021 Jul; 27(5):1311-1314. PubMed ID: 33054691
[TBL] [Abstract][Full Text] [Related]
20. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]